EUVIMEDEUVIMED entdecken
Open Access

Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy

Sharla M Birch iD, Michael W Lawlor iD, Thomas J Conlon, Lee-Jae Guo iD, Julie M Crudele iD, Eleanor C Hawkins iD, Peter P Nghiem iD, Mihye Ahn iD, Hui Meng iD, Margaret J Beatka, Brittany A Fickau iD, Juan C Prieto iD und 19 weitere

Science Translational Medicine · 04.01.2023 · 15 (677)

DOI: 10.1126/scitranslmed.abo1815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 04.01.2023. Verfasst von Sharla M Birch und 30 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M University, College of Veterinary Medicine and Biomedical Sciences, College Station, TX 77843, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Animal, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by the absence of dystrophin, a membrane-stabilizing protein encoded by the DMD gene. Although mouse models of DMD provide insight into the potential of a corrective therapy, data from genetically homologous large animals, such as the dystrophin-deficient golden retriever muscular dystrophy (GRMD) model, may more readily translate to humans. To evaluate the clinical translatability of an adeno-associated virus serotype 9 vector (AAV9)–microdystrophin (μDys5) construct, we performed a blinded, placebo-controlled study in which 12 GRMD dogs were divided among four dose groups [control, 1 × 10 13 vector genomes per kilogram (vg/kg), 1 × 10 14 vg/kg, and 2 × 10 14 vg/kg; n = 3 each], treated intravenously at 3 months of age with a canine codon-optimized microdystrophin construct, rAAV9-CK8e-c-μDys5, and followed for 90 days after dosing. All dogs received prednisone (1 milligram/kilogram) for a total of 5 weeks from day −7 through day 28. We observed dose-dependent increases in tissue vector genome copy numbers; μDys5 protein in multiple appendicular muscles, the diaphragm, and heart; limb and respiratory muscle functional improvement; and reduction of histopathologic lesions. As expected, given that a truncated dystrophin protein was generated, phenotypic test results and histopathologic lesions did not fully normalize. All administrations were well tolerated, and adverse events were not seen. These data suggest that systemically administered AAV-microdystrophin may be dosed safely and could provide therapeutic benefit for patients with DMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, AnimalMuscular Dystrophy, DuchenneAnimalsDogsHumansInfant, NewbornMiceDystrophinGenetic TherapyHeartMuscle, SkeletalMuscles

Substanzen

Dystrophin

Autor:innen und Institutionen

  • Texas A&M University, College of Veterinary Medicine and Biomedical Sciences, College Station, TX 77843, USA.
  • Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA.
  • University of Washington, Seattle, WA 98109, USA.
  • College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.
  • University of Nevada-Reno, Reno, NV 89557, USA.

ORCID-Profile: Sharla M Birch, Michael W Lawlor, Lee-Jae Guo, Julie M Crudele, Eleanor C Hawkins, Peter P Nghiem, Mihye Ahn, Hui Meng, Brittany A Fickau, Juan C Prieto, Martin A Styner, Michael J Struharik, Diane Golebiowski, Amanda K Bettis, Cynthia J Balog-Alvarez, Kirsten E Coleman, Xiufang Pan, Stephen D Hauschka, Carl A Morris, Dongsheng Duan, Jeffrey S Chamberlain, Barry J Byrne, Joe N Kornegay

Förderung

  • NIAMS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Birch, S. M., Lawlor, M. W., Conlon, T. J., Guo, L. J., Crudele, J. M., Hawkins, E. C., Nghiem, P. P., Ahn, M., Meng, H., Beatka, M. J., Fickau, B. A., Prieto, J. C., Styner, M. A., Struharik, M. J., Shanks, C., Brown, K. J., Golebiowski, D., Bettis, A. K., Balog-Alvarez, C. J., …, & Kornegay, J. N. (2023). Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Science Translational Medicine, 15(677). https://doi.org/10.1126/scitranslmed.abo1815

Vancouver

Birch SM, Lawlor MW, Conlon TJ, Guo LJ, Crudele JM, Hawkins EC, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Science Translational Medicine. 2023;15(677). doi:10.1126/scitranslmed.abo1815

BibTeX
@article{Birch2023,
  author = {Birch, Sharla M and Lawlor, Michael W and Conlon, Thomas J and Guo, Lee-Jae and Crudele, Julie M and Hawkins, Eleanor C and Nghiem, Peter P and Ahn, Mihye and Meng, Hui and Beatka, Margaret J and Fickau, Brittany A and Prieto, Juan C and Styner, Martin A and Struharik, Michael J and Shanks, Courtney and Brown, Kristy J and Golebiowski, Diane and Bettis, Amanda K and Balog-Alvarez, Cynthia J and Clement, Nathalie and Coleman, Kirsten E and Corti, Manuela and Pan, Xiufang and Hauschka, Stephen D and Gonzalez, J Patrick and Morris, Carl A and Schneider, Joel S and Duan, Dongsheng and Chamberlain, Jeffrey S and Byrne, Barry J and Kornegay, Joe N},
  title = {Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {677},
  doi = {10.1126/scitranslmed.abo1815}
}
Kostenlos starten →